|
|
|
|
 |
| The University of Chicago Hematology/Oncology section conducts a wide range of cutting edge research for advancements in the treatment of cancer in both the laboratory and clinical setting. Some of our basic research includes the following fields: developmental biology and genetics, cellular biology including intracellular pathways and signal transduction, drug resistance and development, cytogenetics, tumor immunology, transplant biology, and protein targeting. Much of our basic research carries over into clinical studies. With our clinical research, the Hematology/Oncology section believes in a multimodality (a combination of treatments) and multi-disciplinary approach that includes laboratory research and clinical research in our pursuit for the best treatment and care for our patients. One of the only institutions to have clinical trials in Phase I, Phase II, and Phase III of drug development, the distinguished faculty have ongoing investigations in each of these phases. By interacting with cooperative research groups like the Cancer and Leukemia Group B (CALGB), our cancer program is able to offer advantages to patients with all types of cancer by having access to top research teams across the U.S. and the world. | ||
©1998-99 The University of Chicago®